Two-Dose Recombinant Zoster Vaccine Effective in Older Adults
Two doses of the recombinant zoster vaccine (RZV) are effective in older adults, including immunocompromised adults.
A study published in the Annals of Internal Medicine found that RZV effectiveness is similar among immunocompetent and immunocompromised individuals.
- Researchers from the University of North Carolina at Chapel Hill examined RZV effectiveness using target trial emulation.
- They accounted for prior receipt of a live zoster vaccine (ZVL) and immunocompetence.
The analysis included 12 sequential trials of at least 12 months’ duration and estimated pooled vaccine effectiveness across the trials.
Two RZV doses are effective among older adults, with similar vaccine efficacy found among immunocompetent vs immunocompromised individuals.
Author's summary: RZV effective in older adults regardless of prior vaccination.